• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

54
14
12
10
10

COUNTRY

4
4
3
3
2

CATEGORIES

  • 28
  • 28
  • 25
  • 21
  • 16
  • 8
  • 7
  • 5
  • 5
  • 4
  • 3
  • 3
  • 3
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
SHOW ALL…

PRICE

52
57
72
159

PUBLISHED

1
11
46
159

PRODUCT TYPE

106
50
3

Search "Bayer: Performance, Products, Pipeline and Potential" returned 159 results.

PRODUCT TITLE

Bayer AG (BAYN) - Financial and Strategic SWOT Analysis Review

Bayer AG (BAYN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData...

April 2014
FROM

Bayer HealthCare AG - Strategic SWOT Analysis Review

Bayer HealthCare AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed...

May 2014
FROM

Bayer HealthCare Pharmaceuticals - Strategic SWOT Analysis Review

Bayer HealthCare Pharmaceuticals - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains...

June 2014
FROM

Big Pharma's Key Lifecycle Management Strategies - Maximizing the Market Potential

“Big Pharma's Key Lifecycle Management Strategies: Maximizing the Market Potential ” provides key data, information and analysis on the key lifecycle management strategies implemented by pharmaceutical...

February 2010
FROM
Orphan Drug Markets in Europe: Key Developments and the Strategies of Major Pharmaceutical Companies Orphan Drug Markets in Europe: Key Developments and the Strategies of Major Pharmaceutical Companies - Product Thumbnail Image

Orphan Drug Markets in Europe: Key Developments and the Strategies of Major Pharmaceutical Companies

The successful introduction of orphan products in Europe remains problematic for the developers, although they can seek to alleviate some of the issues by carefully developing a launch strategy The...

November 2011
FROM
Bayer Aspirin Protect-Drug Insights,2014 Bayer Aspirin Protect-Drug Insights,2014 - Product Thumbnail Image

Bayer Aspirin Protect-Drug Insights,2014

“Bayer Aspirin Protect - Drug Insights, 2014” provides Bayer Aspirin Protect marketed details and API Manufacturers details across the globe along with the location. In addition, it covers sales estimates...

February 2015
FROM

Lemtrada (Multiple Sclerosis) - Forecast and Market Analysis to 2022

Lemtrada (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Lemtrada (Multiple Sclerosis) - Forecast and Market...

March 2013
FROM

Masitinib (Multiple Sclerosis) - Forecast and Market Analysis to 2022

Masitinib (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Masitinib (Multiple Sclerosis) - Forecast and Market...

March 2013
FROM

Tcelna (Multiple Sclerosis) - Forecast and Market Analysis to 2022

Tcelna (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Tcelna (Multiple Sclerosis) - Forecast and Market Analysis...

March 2013
FROM

BG-12 (Multiple Sclerosis) - Forecast and Market Analysis to 2022

BG-12 (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “BG-12 (Multiple Sclerosis) - Forecast and Market Analysis...

March 2013
FROM

Ocrelizumab (Multiple Sclerosis) - Forecast and Market Analysis to 2022

Ocrelizumab (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Ocrelizumab (Multiple Sclerosis) - Forecast and...

March 2013
FROM

NU-100 (Multiple Sclerosis) - Forecast and Market Analysis to 2022

NU-100 (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “NU-100 (Multiple Sclerosis) - Forecast and Market Analysis...

March 2013
FROM

Laquinimod (Multiple Sclerosis) - Forecast and Market Analysis to 2022

Laquinimod (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Laquinimod (Multiple Sclerosis) - Forecast and Market...

March 2013
FROM

Pharmaceutical Products of the Future: 50-Company Biopharma and Traditional Pipeline Analysis to 2016

What Will the Pharma Industry Look Like in 5 Years? There are an estimated 724 projects in development from the top 50 pharmaceutical companies.  Together, they have the potential to add billions...

August 2012
FROM

KOL Insight: Prostate Cancer: Competition Intensifies in Race to the Top

The Prostate Cancer market has seen a number of progressive changes in recent years The launches of Johnson & Johnson's Zytiga (abiraterone acetate) and Medivation/Astellas's Xtandi (enzalutamide) has...

June 2013
FROM

Betaseron/Betaferon (Multiple Sclerosis) - Forecast and Market Analysis to 2022

Betaseron/Betaferon (Multiple Sclerosis) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Betaseron/Betaferon (Multiple Sclerosis)...

March 2013
FROM

Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market

Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market Summary GBI Research, the leading business intelligence provider, has...

February 2011
FROM

PharmaPoint: Multiple Sclerosis - Italy Drug Forecast and Market Analysis to 2022

PharmaPoint: Multiple Sclerosis - Italy Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Multiple Sclerosis - Italy Drug Forecast and...

March 2013
FROM

PharmaPoint: Multiple Sclerosis - Germany Drug Forecast and Market Analysis to 2022

PharmaPoint: Multiple Sclerosis - Germany Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Multiple Sclerosis - Germany Drug Forecast...

March 2013
FROM
The Global Pain Therapeutics Market, 4th Edition: Market Trends & R&D Insights The Global Pain Therapeutics Market, 4th Edition: Market Trends & R&D Insights - Product Thumbnail Image

The Global Pain Therapeutics Market, 4th Edition: Market Trends & R&D Insights

Pain continues to present numerous challenges to the biopharmaceutical industry According to the American Academy of Pain Medicine, over 76 million Americans suffer from pain Indeed, pain affects more...

October 2010
FROM
Loading Indicator

Our Clients

Symantec Corporation Sonoco Products Company Tiffany & Co. ITT Corporation Exxon Mobil Corp. Samsonite International S.A. Kellogg's Co.